

Profiling Human TCR Repertoire Diversity with SMART Technology

Sarah Taylor, Nao Yasuyama, Andrew Farmer¹



Takara Bio USA, Inc., 1290 Terra Bella Ave., Mountain View, CA 94043

¹Corresponding Author: Andrew_Farmer@clontech.com

Introduction

Profiling T-cell receptor (TCR) repertoires involves characterizing the diversity of TCR nucleotide sequences in a sample, and is an increasingly popular approach for analyzing the composition of the adaptive immune system. While low-throughput approaches have yielded important insights concerning TCR repertoire dynamics, development of next-generation sequencing (NGS) technologies has dramatically expanded research prospects.


Using SMART[®] technology, we have developed a method for NGS library preparation for TCR profiling that employs a 5' RACE-like approach to capture full-length variable regions of TCR- α and/or TCR- β subunits. With this approach, 10 ng–3 μ g of input RNA or 50–10,000 purified T cells undergo reverse transcription using dT priming. Following first-strand cDNA synthesis, semi-nested PCR is used to amplify TCR-specific sequences and add Illumina[®] sequencing adapters.

Our workflow enables the user to obtain sequencing-ready TCR libraries from RNA in ~2.5 hours of hands-on time. Whereas approaches that utilize genomic DNA as starting material require multiplexed PCR strategies, RNA-based amplification of TCR sequences uses single primer pairs for each subunit. In this way, our approach minimizes the likelihood of sample misrepresentation due to amplification biases.

With our approach, we have generated and sequenced libraries for both TCR- α and TCR- β from various samples of peripheral blood RNA, and for a range of input amounts. For each library >70% of reads were on-target, and a comparison of results obtained for varying input amounts from the same sample indicated that clonotype frequencies were represented consistently for each. A sensitivity assay indicated that RNA corresponding to a single clonotype could be detected above background levels when spiked into input RNA at a relative concentration of 0.1%. Analysis of sequencing libraries generated from blood cancer patient samples demonstrated the suitability of our approach for clinical research applications.

Methods and data

1 TCR sequencing library preparation




Library preparation workflow and PCR strategy for TCR profiling using the SMARTer[®] Human TCR a/b Profiling Kit. First-strand cDNA synthesis is primed by the TCR dT Primer and performed by an MMLV-derived reverse transcriptase (RT). Upon reaching the 5' end of each mRNA molecule, the RT adds non-templated nucleotides to the first-strand cDNA. The SMART-Seq[®] v4 Oligonucleotide contains a sequence that is complementary to the non-templated nucleotides added by the RT, and hybridizes to the first-strand cDNA. In the template-switching step, the RT uses the remainder of the SMART-Seq v4 Oligonucleotide as a template for the incorporation of an additional sequence on the end of the first-strand cDNA. Full-length variable regions of TCR cDNA are selectively amplified by PCR using primers that are complementary to the oligonucleotide-templated sequence (SMART Primer 1) and the constant region(s) of TCR- α and/or TCR- β subunits (TCR a/b Human Primer 1). A subsequent round of PCR is performed to further amplify variable regions of TCR- α and/or TCR- β subunits and incorporate adapter sequences, using TCR Primer 2 and TCR a/b Human Primer 2. Included in the primers are adapter and index sequences (read 2 + 17 + P7 and read 1 + 15 + P5, respectively) that are compatible with the Illumina sequencing platform. Following purification, size selection, and quality analysis, TCR cDNA libraries are sequenced on the Illumina platform using 300 bp paired-end reads.

References

Bolotin, D. A., Poslavsky, S., Mitrophanov, I., Shugay, M., Mamedov, I. Z., Putintseva, E. V., & Chudakov, D. M. (2015) MiXCR: software for comprehensive adaptive immunity profiling. *Nat. Methods* 12(5):380–381.


Takara Bio USA, Inc. • A Takara Bio Company
United States/Canada: +1 800.662.2566 • Asia/Pacific: +1 503.919.7200 • Europe: +33 (0)1 2904.6880 • Japan: +81 (0)77.565.6999
FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES. © 2016 Takara Bio Inc. All rights reserved. All trademarks are the property of Takara Bio Inc. or its affiliates in the U.S. and/or other countries or their respective owners. Certain trademarks may not be registered in all jurisdictions. Additional product, intellectual property, and restricted use information is available at <http://www.clontech.com>.

2 Consistency across varying input amounts




Sequencing reads on target, correlation of clonotype count data, and chord diagrams of TCR- β clonotype distributions observed for varying sample input amounts. To evaluate the performance of the kit for a range of input amounts, the SMARTer workflow was performed on three different amounts of peripheral blood RNA (10 ng, 100 ng, and 1,000 ng) and the resulting cDNA libraries were sequenced. Sequencing outputs were downsampled to ~260,000 reads, and processed using an application provided by Illumina via the BaseSpace website (Bolotin et al., 2015). **Panel A.** Percentages of sequencing reads that map to CDR3 regions in either TCR- α (blue) or TCR- β (purple) for each indicated sample input amount. For each sample amount analyzed, >70% of sequencing reads mapped to a CDR3 region in either TCR- α or TCR- β . These results demonstrate that the SMARTer approach can capture and amplify TCR sequences from total RNA with considerable specificity across a wide range of sample input amounts. **Panel B.** Correlation of clonotype count data for 100 ng input RNA vs. 1,000 ng input RNA. Comparison of clonotype count data yielded a Pearson correlation coefficient (R) of 0.80 and a Spearman coefficient (ρ) of 0.80, a result that speaks to the robustness of the SMARTer approach for input sample amounts that vary by at least one order of magnitude. **Panels C-E.** The distribution of TCR- β clonotypes identified in the sequencing data depicted by chord diagrams. Each arc (on the periphery of each diagram) represents a V or J gene segment and is scaled lengthwise according to the relative proportion at which the gene segment is represented in the dataset. Each chord (connecting the arcs) represents a set of clonotypes which include the indicated V-J combination, and is weighted according to the relative abundance of that combination in the dataset. **Panel C.** Chord diagram for 10 ng input of PBMC RNA. **Panel D.** Chord diagram for 100 ng input of PBMC RNA. **Panel E.** Chord diagram for 1,000 ng input of PBMC RNA. Comparison of the three diagrams suggests that the indicated clonotypes are identified at similar proportions for each RNA input amount.

3 Assessing sensitivity and reproducibility



Assessing the sensitivity and reproducibility of the SMARTer approach. In order to assess the sensitivity of the SMARTer approach, the protocol was performed in replicate on PBMC RNA samples spiked at varying concentrations (10%, 1%, 0.1%, 0.01%, and 0.001%) with RNA obtained from a homogenous population of Leukemic Jurkat T cells (TRAV8-4-TRAJ3, TRBV12-3-TRBJ1-2 clonotype). **Panel A.** Correlation between concentration of spiked-in Jurkat RNA and number of TRBV12-3-TRBJ1-2-specific sequence reads. Numbers along the X-axis indicate serial-diluted concentrations of spiked-in Jurkat RNA (by mass): 1 = 10%; 2 = 1%; 3 = 0.1%; 4 = 0.01%; 5 = 0.001%. Count data for TRBV12-3-TRBJ1-2-specific sequence reads were normalized by subtracting the number of corresponding reads obtained for negative control samples consisting of unspiked PBMC RNA. Normalized count data were then \log_{10} transformed. Circles and triangles correspond to experimental replicates for each sample concentration. Linear regression analysis revealed a statistically significant correlation ($p = 3.93 \times 10^{-14}$, $R^2 = 0.99$) between the amount of spiked-in Jurkat RNA and the number of TRBV12-3-TRBJ1-2-specific sequence reads. These results demonstrate that differences in the relative abundance of transcripts for a particular TCR clonotype are faithfully and reproducibly represented in sequencing libraries generated using the SMARTer approach. **Panel B.** Count data, signal-to-noise ratios, and statistical analysis for TRBV12-3-TRBJ1-2-specific sequence reads obtained from spiked RNA samples. Signal-to-noise ratios were generated using the mean counts of TRBV12-3-TRBJ1-2-specific sequence reads for each pair of experimental replicates. Rows highlighted in yellow include concentrations of spiked-in Jurkat RNA for which statistically significant elevations in TRBV12-3-TRBJ1-2-specific sequence reads were detected relative to background counts observed for unspiked negative control RNA samples. Added Jurkat RNA at a concentration of 0.1% was detectable above background in the sequencing output ($p < 0.005$) at a depth of ~275,000 reads, evidence of the sensitivity afforded by the SMARTer approach.

4 Analysis of clinical samples from blood cancer patients



Sequencing reads on target and chord diagrams of TCR- α and TCR- β clonotype distributions observed for two blood cancer patient samples. To test the performance of the workflow on clinically relevant samples, libraries were generated from PBMC RNA obtained from two blood cancer patients, and sequencing was performed as described previously. **Panel A.** Analysis of sequencing data for PBMC RNA obtained from a patient with T-cell polymorphous leukemia. 89% of reads mapped to either TCR- α or TCR- β sequences. **Panels B and C.** Chord diagrams of TCR- α and TCR- β clonotypes identified from the sequencing data indicate the predominance of a single clonotype for TCR- α and TCR- β , respectively, in this patient. **Panel D.** Analysis of sequencing data for PBMC RNA obtained from a patient with mycosis fungoides and the Sézary syndrome. 73% of reads mapped to either TCR- α or TCR- β sequences. **Panels E and F.** Chord diagrams of TCR- α and TCR- β clonotypes identified from the sequencing data indicate the presence of an array of clonotypes for TCR- α and TCR- β , respectively, in this patient.

Conclusions

- Our SMARTer Human TCR a/b Profiling Kit provides a streamlined workflow for the generation of Illumina-ready TCR sequencing libraries that minimizes the likelihood of amplification biases by avoiding multiplex PCR
- The SMARTer approach captures entire TCR variable regions and allows for analysis of both α and β chains in the same experiment
- The kit performs reliably for a range of total RNA or T-cell input amounts, and the data generated consists largely of on-target reads
- The sensitivity afforded by the SMARTer approach is such that clonotype-specific TCR RNA added at a concentration of 0.1% is detectable above background and reproducibly represented in sequencing libraries produced with the kit
- The kit yields high-quality data when used to analyze clinical samples obtained from blood cancer patients



Scan to download your copy of this poster, or visit http://info.clontech.com/human_TCR_2016.html

800.662.2566

Visit us at www.clontech.com/ngs

Clontech Takara cellartis